Roflumilast: clinical benefit in patients suffering from COPD

Medicin og biovidenskab

• Roflumilast 100%
• Chronic Obstructive Pulmonary Disease 53%
• Clinical Studies 18%
• Phosphodiesterase 4 Inhibitors 12%
• Inflammation 10%
• Bronchodilator Agents 9%
• Patient Reported Outcome Measures 9%
• Nausea 7%
• Diarrhea 7%
• Weight Loss 7%
• Adrenal Cortex Hormones 6%
• Disease Progression 6%
• Therapeutics 5%
• Quality of Life 5%
• Morbidity 5%
• Mortality 4%
• Pharmaceutical Preparations 3%